ERYP
ERYTECH Pharma S.A. [ERYP] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ERYP Stock Summary
In the News
ERYP Financial details
Company Rating
Neutral
Market Cap
47.38M
Income
614K
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
49
Optionable
No
Shortable
Yes
Earnings
26 Apr 2023
P/E
35.99
Forward P/E
-
PEG
-3.58
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.01
EPS next Y
-
EPS next Q
-
EPS this Y
-99.67%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-67.78%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-211.76%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0.44%
Inst Trans
0.36%
ROA
-
ROE
4%
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.3-1.472
52W High
-
52W Low
-
RSI
-
Rel Volume
0.02
Avg Volume
148.59K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
2.12912
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
ERYP Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.23 | 0.19 | 0 | 0 | 0 | |
| Net income per share | -2.13 | -3.49 | -3.99 | -2.27 | -0.01 | |
| Operating cash flow per share | -2.19 | -2.41 | -2.81 | -2.4 | -1.02 | |
| Free cash flow per share | -2.98 | -3.54 | -2.87 | -2.41 | -1.03 | |
| Cash per share | 7.49 | 4.08 | 2.42 | 1.44 | 1.25 | |
| Book value per share | 8.12 | 4.77 | 1.44 | 0.96 | 0.76 | |
| Tangible book value per share | 8.03 | 4.74 | 1.41 | 0.96 | 0.76 | |
| Share holders equity per share | 8.12 | 4.77 | 1.44 | 0.96 | 0.76 | |
| Interest debt per share | 0.11 | 0.87 | 1.78 | 1.16 | 0.48 | |
| Market cap | 105.91M | 117.54M | 138.82M | 49.16M | 9.6M | |
| Enterprise value | -26.44M | 58.49M | 121.82M | 40.84M | -15.63M | |
| P/E ratio | -2.77 | -1.88 | -1.89 | -0.91 | -42.09 | |
| Price to sales ratio | 25.6 | 34.94 | 0 | 0 | 0 | |
| POCF ratio | -2.7 | -2.71 | -2.68 | -0.87 | -0.3 | |
| PFCF ratio | -1.98 | -1.85 | -2.63 | -0.86 | -0.3 | |
| P/B Ratio | 0.73 | 1.37 | 5.23 | 2.15 | 0.41 | |
| PTB ratio | 0.73 | 1.37 | 5.23 | 2.15 | 0.41 | |
| EV to sales | -6.39 | 17.39 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 0.71 | -0.96 | -1.79 | -0.86 | 0.69 | |
| EV to operating cash flow | 0.67 | -1.35 | -2.36 | -0.72 | 0.49 | |
| EV to free cash flow | 0.49 | -0.92 | -2.3 | -0.72 | 0.49 | |
| Earnings yield | -0.36 | -0.53 | -0.53 | -1.09 | -0.02 | |
| Free cash flow yield | -0.51 | -0.54 | -0.38 | -1.16 | -3.32 | |
| Debt to equity | 0.01 | 0.17 | 1.03 | 1.11 | 0.58 | |
| Debt to assets | 0.01 | 0.12 | 0.34 | 0.38 | 0.3 | |
| Net debt to EBITDA | 3.54 | 0.97 | 0.25 | 0.18 | 1.11 | |
| Current ratio | 7.26 | 4.1 | 1.69 | 2 | 3.65 | |
| Interest coverage | -4.85K | -41.8 | -12.86 | -26.43 | -2.05 | |
| Income quality | 1.03 | 0.69 | 0.71 | 1.06 | 139.32 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 3.53 | 5.1 | 0 | 0 | 0 | |
| Research and developement to revenue | -4.77 | 15.52 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0 | 0 | |
| Capex to operating cash flow | 0.36 | 0.46 | 0.02 | 0.01 | 0 | |
| Capex to revenue | -3.44 | -5.98 | 0 | 0 | 0 | |
| Capex to depreciation | -17.85 | -4.78 | -0.23 | -0.06 | -0.03 | |
| Stock based compensation to revenue | 0.59 | 0.4 | 0 | 0 | 0 | |
| Graham number | 19.73 | 19.36 | 11.38 | 7.02 | 0.35 | |
| ROIC | -0.3 | -0.57 | -1.06 | -0.97 | 0.05 | |
| Return on tangible assets | -0.23 | -0.53 | -0.92 | -0.81 | 0 | |
| Graham Net | 6.7 | 2.49 | -0.33 | -0.28 | 0.61 | |
| Working capital | 129.26M | 61.7M | 20.29M | 20.04M | 30.96M | |
| Tangible asset value | 143.99M | 84.96M | 25.95M | 22.83M | 23.48M | |
| Net current asset value | 127.67M | 48.6M | -4.23M | -3.88M | 20.31M | |
| Invested capital | 0.01 | 0.17 | 1.03 | 1.11 | 0.58 | |
| Average receivables | 7.11M | 7.75M | 5.08M | 4.28M | 3.38M | |
| Average payables | 12.37M | 10.86M | 4.89M | 3.6M | 2.02M | |
| Average inventory | 786K | 877K | 179K | 0 | 634K | |
| Days sales outstanding | 853.84 | 631.91 | 0 | 0 | 0 | |
| Days payables outstanding | 181.64 | 35.48 | 29.83 | 0 | 0 | |
| Days of inventory on hand | 15.22 | 2.5 | 0 | 0 | 0 | |
| Receivables turnover | 0.43 | 0.58 | 0 | 0 | 0 | |
| Payables turnover | 2.01 | 10.29 | 12.24 | 0 | 0 | |
| Inventory turnover | 23.97 | 145.79 | 0 | 0 | 0 | |
| ROE | -0.26 | -0.73 | -2.76 | -2.35 | -0.01 | |
| Capex per share | -0.79 | -1.12 | -0.06 | -0.01 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-22 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-22 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.36 | 0.35 | -0.17 | 0.19 | 0 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0 | 1.75 | 0 | 1.25 | 0 | |
| Book value per share | 0 | 0.72 | 0 | 0.76 | 0 | |
| Tangible book value per share | 0 | 0.72 | 0 | 0.76 | 0 | |
| Share holders equity per share | 0 | 0.72 | 0 | 0.76 | 0 | |
| Interest debt per share | 0 | 0.13 | 0 | 0.45 | 0 | |
| Market cap | 49.11M | 33.32M | 17.35M | 9.6M | 0 | |
| Enterprise value | 0 | -16.01M | 0 | -15.63M | 0 | |
| P/E ratio | -1.11 | 0.77 | -0.84 | 0.4 | 0 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | 0 | 0 | 0 | 0 | 0 | |
| PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
| P/B Ratio | 0 | 1.49 | 0 | 0.41 | 0 | |
| PTB ratio | 0 | 1.49 | 0 | 0.41 | 0 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 0 | -1.09 | 0 | -5.04 | 0 | |
| EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
| Earnings yield | -0.23 | 0.33 | -0.3 | 0.62 | 0 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0.18 | 0 | 0.58 | 0 | |
| Debt to assets | 0 | 0.06 | 0 | 0.3 | 0 | |
| Net debt to EBITDA | 0 | -3.37 | 0 | -8.14 | 0 | |
| Current ratio | 0 | 2.25 | 0 | 3.65 | 0 | |
| Interest coverage | -53.03 | 370.82 | -9.11 | 5.54 | 0 | |
| Income quality | 0 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0 | 2.39 | 0 | 1.81 | 0 | |
| ROIC | 0 | 0.31 | 0 | 0.15 | 0 | |
| Return on tangible assets | 0 | 0.17 | 0 | 0.13 | 0 | |
| Graham Net | 0 | 0.47 | 0 | 0.61 | 0 | |
| Working capital | 0 | 34.56M | 0 | 30.96M | 0 | |
| Tangible asset value | 0 | 22.43M | 0 | 23.48M | 0 | |
| Net current asset value | 0 | 18.57M | 0 | 20.31M | 0 | |
| Invested capital | 0 | 0.18 | 0 | 0.58 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 1.27M | |
| Average payables | 0 | 0 | 0 | 0 | 781K | |
| Average inventory | 0 | 0 | 0 | 0 | 634K | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0 | 0.49 | 0 | 0.25 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ERYP Frequently Asked Questions
What is ERYTECH Pharma S.A. stock symbol ?
ERYTECH Pharma S.A. is a FR stock and trading under the symbol ERYP
What is ERYTECH Pharma S.A. stock quote today ?
ERYTECH Pharma S.A. stock price is $- today.
Is ERYTECH Pharma S.A. stock public?
Yes, ERYTECH Pharma S.A. is a publicly traded company.
Company Profile
- Volume Average 148.59K
- Market Capitalization 47.38M
- Employee 49
- CEO Mr. Gil Beyen M.B.A.
- Headquarters Lyon,FR
- IPO Date 2016-07-05
-
Website
https://www.erytech.com 
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
